Evidence map›Paper›PMID 35495861›Full record

ArticleCJC open2022

Effect of New Evidence on Antithrombotic Therapies in Atrial Fibrillation Patients Who Undergo Percutaneous Coronary Intervention in Alberta, Canada.

Theresa E Eberhardt, Tammy J Bungard, Michelle M Graham, Michelle Picard, Grace T Wang, Margaret L Ackman

Abstract read
In one paragraph

Article in CJC open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Theresa E EberhardtPharmacy Services, Alberta Health Services, Edmonton, Alberta. Canada.
Tammy J BungardDivision of Cardiology, Department of Medicine, University of Alberta Hospital, Edmonton, Alberta, Canada.
Michelle M GrahamDivision of Cardiology, Department of Medicine, University of Alberta Hospital, Edmonton, Alberta, Canada.
Michelle PicardPharmacy Services, Alberta Health Services, Edmonton, Alberta. Canada.
Grace T WangHealth Research Methods and Analytics, Alberta Health Services, Edmonton, Alberta, Canada.
Margaret L AckmanPharmacy Services, Alberta Health Services, Edmonton, Alberta. Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Trials have addressed the combined use of direct oral anticoagulants (DOACs) and antiplatelets in atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI). These trials may have changed prescribing patterns. Methods: This administrative audit of Albertans with AF undergoing PCI described antithrombotic therapy before vs after publication of the PIONEER AF-PCI (An O Results: Cohorts were similar before ( Conclusions: Significantly more patients were prescribed anticoagulation therapy after the publication of the results of the PIONEER AF-PCI trial than before, and the choice of agent favoured DOAC over warfarin. Almost half of patients were not on anticoagulants, a situation that requires further investigation, to ensure that AF patients are being optimally managed post-PCI.

Identifiers

PMID35495861
PMCPMC9039572

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.